Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort
Abstract Background Second-generation tau tracers for positron emission tomography (PET) show high affinity for paired helical filaments tau deposits characteristic of Alzheimer´s disease and low off-target binding. Differences in their chemical structure though may lead to variations in their regio...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | Alzheimer’s Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13195-024-01622-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846148053127397376 |
|---|---|
| author | Matteo Tonietto Oscar Sotolongo-Grau Núria Roé-Vellvé Santiago Bullich Juan Pablo Tartari Ángela Sanabria Ainhoa García-Sánchez Edilio Borroni Christopher Galli Esther Pérez-Martínez Joan Castell-Conesa Isabel Roca Lluís Tárraga Agustín Ruiz Andrew W. Stephens Mercè Boada Gregory Klein Marta Marquié on behalf of the FACEHBI study group on behalf of the AMYPAD consortium |
| author_facet | Matteo Tonietto Oscar Sotolongo-Grau Núria Roé-Vellvé Santiago Bullich Juan Pablo Tartari Ángela Sanabria Ainhoa García-Sánchez Edilio Borroni Christopher Galli Esther Pérez-Martínez Joan Castell-Conesa Isabel Roca Lluís Tárraga Agustín Ruiz Andrew W. Stephens Mercè Boada Gregory Klein Marta Marquié on behalf of the FACEHBI study group on behalf of the AMYPAD consortium |
| author_sort | Matteo Tonietto |
| collection | DOAJ |
| description | Abstract Background Second-generation tau tracers for positron emission tomography (PET) show high affinity for paired helical filaments tau deposits characteristic of Alzheimer´s disease and low off-target binding. Differences in their chemical structure though may lead to variations in their regional tau uptake and off-target signal. In this work, we aimed to compare the in-vivo uptake of tau tracers [18F]PI-2620 and [18F]RO948 in the early stages of the AD continuum. Methods Data from the TAU-PET FACEHBI clinical trial (EUDRA-CT 2021–000473-83) were analyzed. All participants were non-demented and underwent tau imaging with [18F]PI-2620 and [18F]RO948 PET within 3 months, amyloid imaging with [18F]Florbetaben and brain magnetic resonance imaging. Tau PET standardized uptake values ratios (SUVR) were calculated in Braak and typical off-target regions using the inferior cerebellar cortex as a reference region. Results The cohort consisted of 18 individuals with subjective cognitive decline (n = 13) and mild cognitive impairment (n = 5), with centiloid values ranging from 17 to 159. Both tau tracers showed similar tau pathology distribution but presented a distinct off-target signal pattern on visual read. SUVR measurements for [18F]PI-2620 and [18F]RO948 were highly correlated in all Braak regions (R2 range [0.65–0.80]). Regarding off-target signal, [18F]PI-2620 had higher SUVRs in vascular structures, and [18F]RO948 had higher SUVRs in the skull/meninges. Conclusions In a cohort of individuals at early stages of the AD continuum, tau PET tracers [18F]PI-2620 and [18F]RO948 showed similar in-vivo uptake in all Braak regions and distinct off-target signal. These preliminary results support the development of standardized quantification scales for tau deposition that are tracer-independent. Trial registration AEMPS EudraCT 2021–000473-83. Registered 30 December 2021. |
| format | Article |
| id | doaj-art-a701a98f52f341ec8cfdb4e50416d2e5 |
| institution | Kabale University |
| issn | 1758-9193 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Alzheimer’s Research & Therapy |
| spelling | doaj-art-a701a98f52f341ec8cfdb4e50416d2e52024-12-01T12:13:09ZengBMCAlzheimer’s Research & Therapy1758-91932024-11-0116111310.1186/s13195-024-01622-5Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohortMatteo Tonietto0Oscar Sotolongo-Grau1Núria Roé-Vellvé2Santiago Bullich3Juan Pablo Tartari4Ángela Sanabria5Ainhoa García-Sánchez6Edilio Borroni7Christopher Galli8Esther Pérez-Martínez9Joan Castell-Conesa10Isabel Roca11Lluís Tárraga12Agustín Ruiz13Andrew W. Stephens14Mercè Boada15Gregory Klein16Marta Marquié17on behalf of the FACEHBI study groupon behalf of the AMYPAD consortiumRoche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, F.Hoffmann-La Roche LtdAce Alzheimer Center Barcelona – Universitat Internacional de CatalunyaLife Molecular Imaging GmbHLife Molecular Imaging GmbHAce Alzheimer Center Barcelona – Universitat Internacional de CatalunyaAce Alzheimer Center Barcelona – Universitat Internacional de CatalunyaAce Alzheimer Center Barcelona – Universitat Internacional de CatalunyaRoche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, F.Hoffmann-La Roche LtdRoche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, F.Hoffmann-La Roche LtdLife Molecular Imaging GmbHSIMM Imagen MédicaSIMM Imagen MédicaAce Alzheimer Center Barcelona – Universitat Internacional de CatalunyaAce Alzheimer Center Barcelona – Universitat Internacional de CatalunyaLife Molecular Imaging GmbHAce Alzheimer Center Barcelona – Universitat Internacional de CatalunyaRoche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center Basel, F.Hoffmann-La Roche LtdAce Alzheimer Center Barcelona – Universitat Internacional de CatalunyaAbstract Background Second-generation tau tracers for positron emission tomography (PET) show high affinity for paired helical filaments tau deposits characteristic of Alzheimer´s disease and low off-target binding. Differences in their chemical structure though may lead to variations in their regional tau uptake and off-target signal. In this work, we aimed to compare the in-vivo uptake of tau tracers [18F]PI-2620 and [18F]RO948 in the early stages of the AD continuum. Methods Data from the TAU-PET FACEHBI clinical trial (EUDRA-CT 2021–000473-83) were analyzed. All participants were non-demented and underwent tau imaging with [18F]PI-2620 and [18F]RO948 PET within 3 months, amyloid imaging with [18F]Florbetaben and brain magnetic resonance imaging. Tau PET standardized uptake values ratios (SUVR) were calculated in Braak and typical off-target regions using the inferior cerebellar cortex as a reference region. Results The cohort consisted of 18 individuals with subjective cognitive decline (n = 13) and mild cognitive impairment (n = 5), with centiloid values ranging from 17 to 159. Both tau tracers showed similar tau pathology distribution but presented a distinct off-target signal pattern on visual read. SUVR measurements for [18F]PI-2620 and [18F]RO948 were highly correlated in all Braak regions (R2 range [0.65–0.80]). Regarding off-target signal, [18F]PI-2620 had higher SUVRs in vascular structures, and [18F]RO948 had higher SUVRs in the skull/meninges. Conclusions In a cohort of individuals at early stages of the AD continuum, tau PET tracers [18F]PI-2620 and [18F]RO948 showed similar in-vivo uptake in all Braak regions and distinct off-target signal. These preliminary results support the development of standardized quantification scales for tau deposition that are tracer-independent. Trial registration AEMPS EudraCT 2021–000473-83. Registered 30 December 2021.https://doi.org/10.1186/s13195-024-01622-5TauPositron emission tomography[18F]PI-2620[18F]RO948FACEHBISubjective cognitive decline |
| spellingShingle | Matteo Tonietto Oscar Sotolongo-Grau Núria Roé-Vellvé Santiago Bullich Juan Pablo Tartari Ángela Sanabria Ainhoa García-Sánchez Edilio Borroni Christopher Galli Esther Pérez-Martínez Joan Castell-Conesa Isabel Roca Lluís Tárraga Agustín Ruiz Andrew W. Stephens Mercè Boada Gregory Klein Marta Marquié on behalf of the FACEHBI study group on behalf of the AMYPAD consortium Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort Alzheimer’s Research & Therapy Tau Positron emission tomography [18F]PI-2620 [18F]RO948 FACEHBI Subjective cognitive decline |
| title | Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort |
| title_full | Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort |
| title_fullStr | Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort |
| title_full_unstemmed | Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort |
| title_short | Head-to-head comparison of tau PET tracers [18F]PI-2620 and [18F]RO948 in non-demented individuals with brain amyloid deposition: the TAU-PET FACEHBI cohort |
| title_sort | head to head comparison of tau pet tracers 18f pi 2620 and 18f ro948 in non demented individuals with brain amyloid deposition the tau pet facehbi cohort |
| topic | Tau Positron emission tomography [18F]PI-2620 [18F]RO948 FACEHBI Subjective cognitive decline |
| url | https://doi.org/10.1186/s13195-024-01622-5 |
| work_keys_str_mv | AT matteotonietto headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT oscarsotolongograu headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT nuriaroevellve headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT santiagobullich headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT juanpablotartari headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT angelasanabria headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT ainhoagarciasanchez headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT edilioborroni headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT christophergalli headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT estherperezmartinez headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT joancastellconesa headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT isabelroca headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT lluistarraga headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT agustinruiz headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT andrewwstephens headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT merceboada headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT gregoryklein headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT martamarquie headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT onbehalfofthefacehbistudygroup headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort AT onbehalfoftheamypadconsortium headtoheadcomparisonoftaupettracers18fpi2620and18fro948innondementedindividualswithbrainamyloiddepositionthetaupetfacehbicohort |